Print  |  Close

A Phase 3 randomized study to assess the efficacy and safety of Ublituximab in combination with TGR-1202 compared to Obinutuzumab in combination with Chlorambucil in patients with Chronic Lymphocytic Leukemia (CLL)


Active: Yes
Cancer Type: Leukemia NCT ID: NCT02656303
Trial Phases: Phase III Protocol IDs: UTX-TGR-304 (primary)
Eligibility: , Male and Female Study Type: Treatment
Study Sponsor: TG Therapeutics, Inc
NCI Full Details:

Objectives

Primary

To establish that the combination of ublituximab + TGR-1202 is superior to the combination of obinutuzumab + chlorambucil as measured by duration of progressive free survival

 

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.